Aetna Inc. (AET) Stake Increased by Atalanta Sosnoff Capital LLC
Atalanta Sosnoff Capital LLC boosted its position in Aetna Inc. (NYSE:AET) by 71.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 314,562 shares of the company’s stock after buying an additional 130,740 shares during the period. Aetna comprises about 1.7% of Atalanta Sosnoff Capital LLC’s holdings, making the stock its 22nd largest position. Atalanta Sosnoff Capital LLC’s holdings in Aetna were worth $47,760,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of the company. Ibex Wealth Advisors increased its position in shares of Aetna by 3.5% in the fourth quarter. Ibex Wealth Advisors now owns 15,651 shares of the company’s stock worth $1,918,000 after buying an additional 526 shares during the last quarter. Columbus Circle Investors increased its position in shares of Aetna by 358.8% in the first quarter. Columbus Circle Investors now owns 51,831 shares of the company’s stock worth $6,611,000 after buying an additional 40,535 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Aetna by 0.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 282,165 shares of the company’s stock worth $35,990,000 after buying an additional 875 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Aetna by 31.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,641 shares of the company’s stock worth $6,713,000 after buying an additional 12,648 shares during the last quarter. Finally, Toronto Dominion Bank increased its position in shares of Aetna by 57.0% in the first quarter. Toronto Dominion Bank now owns 95,608 shares of the company’s stock worth $12,194,000 after buying an additional 34,719 shares during the last quarter. Institutional investors and hedge funds own 91.79% of the company’s stock.
Shares of Aetna Inc. (AET) traded up 0.37% during midday trading on Friday, hitting $156.31. 1,225,161 shares of the stock were exchanged. The stock’s 50-day moving average price is $151.67 and its 200-day moving average price is $135.46. The firm has a market capitalization of $51.85 billion, a price-to-earnings ratio of 47.67 and a beta of 0.54. Aetna Inc. has a 1-year low of $104.59 and a 1-year high of $156.49.
Aetna (NYSE:AET) last issued its quarterly earnings results on Tuesday, May 2nd. The company reported $2.71 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.36 by $0.35. The firm had revenue of $15.17 billion during the quarter, compared to the consensus estimate of $15.39 billion. Aetna had a return on equity of 17.75% and a net margin of 1.84%. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter last year, the company posted $2.30 EPS. On average, analysts forecast that Aetna Inc. will post $8.99 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Thursday, July 13th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, July 11th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. Aetna’s dividend payout ratio (DPR) is presently 62.31%.
AET has been the topic of a number of recent analyst reports. CIBC restated an “outperform” rating on shares of Aetna in a report on Monday, April 3rd. Royal Bank Of Canada restated a “buy” rating and set a $145.00 target price on shares of Aetna in a report on Monday, April 24th. Bank of America Corporation restated a “buy” rating and set a $168.00 target price (up from $160.00) on shares of Aetna in a report on Wednesday, May 17th. Oppenheimer Holdings, Inc. restated an “outperform” rating on shares of Aetna in a report on Friday, March 31st. Finally, Morgan Stanley initiated coverage on shares of Aetna in a report on Tuesday, June 6th. They set an “overweight” rating and a $162.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Aetna currently has an average rating of “Buy” and a consensus price target of $152.84.
In other news, Chairman Mark T. Bertolini sold 103,547 shares of Aetna stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $140.79, for a total transaction of $14,578,382.13. Following the completion of the sale, the chairman now owns 659,888 shares in the company, valued at approximately $92,905,631.52. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Margaret M. Mccarthy sold 27,028 shares of Aetna stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $149.23, for a total value of $4,033,388.44. Following the sale, the executive vice president now owns 33,563 shares of the company’s stock, valued at approximately $5,008,606.49. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.
Aetna Company Profile
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
Want to see what other hedge funds are holding AET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aetna Inc. (NYSE:AET).
Receive News & Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related companies with MarketBeat.com's FREE daily email newsletter.